Dear colleagues,
The National Tuberculosis Control Programme of Egypt would like to receive
information on experience with prepacked doses of anti-tuberculous drugs
to be dispensed to patients during both initial and continuation phase of
their treatment.
We are particularly interested if such prepacked daily doses of the drugs
have increased patient-compliance, and, consequently, reduced the level of
defaulting. Furthermore, we would like to have information on the costs
involved.
For your information, the NTP in Egypts uses the treatment regimens
recommended by WHO: for Short Course Chemotherapy 2SRHZ/6HE, for Standard
treatment 2SHE/10HE, and for Retreatment 2SRHZE/1RHZE/5RHE. The treatment
with Rifampicin is fully supervised.
If TB programmes have negative experiences with prepacked drugs, or have
experienced particular problems, our NTP would like to hear about them.
Looking forward to your response, with kind regards,
Pieter J.M. van Maaren
Technical Coordinator
National Tuberculosis Control Project - Egypt
Email: mohdcd@idsc.gov.eg
Fax: +20 - 2 - 354 3197 or 517 0740
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.